UK markets open in 54 minutes

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
7.85+0.44 (+5.94%)
At close: 06:20PM BST

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323
https://adverum.com

Sector(s)
Industry
Full-time employees121

Key executives

NameTitlePayExercisedYear born
Dr. Laurent FischerPresident, CEO & Director1.02MN/A1964
Ms. Linda M. Rubinstein M.A.CFO, Principal Financial Officer & Principal Accounting Officer940.99kN/A1967
Mr. Kishor Peter Soparkar J.D.Chief Operating Officer674.98kN/A1971
Dr. Setareh Seyedkazemi Pharm.D.Chief Development Officer656.84kN/A1974
Dr. R. Andrew Ramelmeier Ph.D.Chief Technology OfficerN/AN/A1962
Dr. Romuald Corbau Ph.D.Chief Scientific OfficerN/AN/A1969
Mr. John W. Rakow J.D.Senior VP & General Counsel954.24kN/A1957
Ms. Dena HouseChief People OfficerN/AN/AN/A
Ms. Carla FiankanSenior Vice President of Regulatory AffairsN/AN/AN/A
Mr. Michael SteelSenior Vice President of QualityN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Corporate governance

Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.